RedHill Biopharma Ltd (RDHL)

[stockguard]

In brief
RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes three FDA-approved gastrointestinal drugs: Movantik® for opioid-induced constipation in adults, Talicia® for Helicobacter pylori (H. pylori) infection in adults, and Aemcolo® for travellers’ diarrhoea in adults. RedHill also has an extensive clinical late-stage development pipeline which includes two Phase 2/3 programs in COVID-19 (opaganib and RHB-107), RHB-204 in a Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease, RHB-104 which successfully completed a first Phase 3 study for Crohn's disease, and RHB-102 which completed a Phase 3 study for acute gastroenteritis and gastritis and a Phase 2 study for IBS-D.

I`m looking forward to the successful trial with their IBS-D study as this is a highly undertreated disability with many people suffering from it and only over the counter medication available.
https://www.proactiveinvestors.com/NASDAQ:RDHL/RedHill-Biopharma/